When Context Is Hard to Come By: External Comparators and How to Use Them

Abstract

External comparators, also referred to as historical or synthetic controls, present transformational opportunities for broad context and insights alongside clinical research results. The recent confluence of access to quality real-world data (RWD), advanced epidemiologic methods, and legislative directives to regulators for expanded use of RWD is increasing interest in real-world external comparators, opening the door to achieve broader generalizability and learn more, faster. In this less standardized area of research, tailored scientific methodology must be applied for external comparators to accomplish clinical development objectives. Here, we describe methodological considerations for design and illustrate how RWD comparators have been used for regulatory and reimbursement decisions.

Keywords

historical controls synthetic controls real-world evidence real-world data benchmark

Get full access to this article

View all access options for this article.

References

Jarow

LaVange

Woodcock

. Multidimensional evidence generation and FDA regulatory decision making: defining and using “real-world” data. JAMA. 2017;318(8):703–704.

Sherman

Anderson

Pan

GJD

, et al.

Real-world evidence—what is it and what can it tell us?

N Engl J Med. 2016;375(23):2293–2297.

Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. https://www.fda.gov/media/78495/download) Updated September 2018. Accessed Mar 7, 2019.

US Food and Drug Administration. 21st Century Cures Act. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act) Updated March 29, 2018. Accessed Mar 7, 2019.

US Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM513027.pdf) Updated September 17, 2018. Accessed February 27, 2019.

US Food and Drug Administration. Framework for FDA’s Real-World Evidence Program. https://www.fda.gov/media/120060/download) Published December 2018. Accessed February 27, 2019.

US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-fdas-new-strategic-framework-advance-use-real-world) Updated December 6, 2018. Accessed May 1, 2019.

US Food and Drug Administration. Breaking Down Barriers Between Clinical Trials and Clinical Care: Incorporating Real World Evidence into Regulatory Decision Making. https://www.fda.gov/news-events/speeches-fda-officials/breaking-down-barriers-between-clinical-trials-and-clinical-care-incorporating-real-world-evidence) Updated January 28, 2019. Accessed May 1, 2019.

US Food and Drug Administration. Rare Diseases: Natural History Studies for Drug Development Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-natural-history-studies-drug-development) Updated March 27, 2019. Accessed May 1, 2019.

10.

Beaver

Howie

Pelosof

, et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018;4(6):849–856.

11.

Patel

. Securing market access with single-arm trial data: Why external comparators could be the answer. IQVIA Solutions. https://www.iqvia.com/blogs/2019/03/securing-market-access-with-single-arm-trial-data. Updated March 14, 2019. Accessed April 24, 2019.

12.

Setoguchi

Gerhard

. Comparator selection. In: Velentgas

Dreyer

Nourjah

, et al, eds. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide. Chap. 5. AHRQ Publication No. 12(13)-EHC099.Rockville, MD: Agency for Healthcare Research and Quality; 2013: 59–70.

13.

Hilal

Sonobol

Prasad

. Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration. JAMA Oncol. 2019;5(6):887–892.

14.

Christian

Dreyer

. “Enriched Studies.” In: Ali

Hartzema

, eds. Post-Authorization Safety Studies of Medicinal Products: The PASS Book. London: Elsevier; 2018:150–157.

15.

Stewart

Norden

Dreyer

, et al. An exploratory analysis of real-world endpoints for assessing outcomes among immunotherapy-treated patients with advanced non-small cell lung cancer [published online ahead of print July 23]. JCO Clin Care Informa. 2019. doi:10.1200/CCI.18.00155.

16.

Lim

Walley

Yuan

, et al. Minimizing patient burden through the use of historical subject-level data in innovative confirmatory clinical trials: review of methods and opportunities. Therapeutic Innovation & Regulatory Science. 2018;52(5):546–559.

17.

US Food and Drug Administration. FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-avelumab-merkel-cell-carcinoma-transcript) Updated May 22, 2017. Accessed Mar 7, 2019.

18.

Broaderick

JM.

Avelumab Approved in Europe for Merkel Cell Carcinoma. OncLive. https://www.onclive.com/web-exclusives/avelumab-approved-in-europe-for-merkel-cell-carcinoma) Published September 21, 2017. Accessed February 8, 2019.

19.

Cowey

Mahnke

Espirito

, et al. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699–1710.

20.

Becker

Lorenz

Ugurel

, et al. Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget. 2017;8(45):79731–79741.

21.

Dreyer

. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Therapeutic Innovation & Regulatory Science. 2018;52(3):362–368.

22.

Gökbuget

Kelsh

Chia

, et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6(9):e473.

23.

Mack

Pavesio

Kelly

, et al. Breaking news: novel design methodology combining a registry with claims data to study fracture non-union. Pharmacoepidemiol Drug Saf. 2017;26(suppl 2):161.

24.

Mack

Pavesio

Kelly

, et al. Making the most of external comparators: a study of fracture healing in patients at risk of non-union. Value Health. 2017:20(3).

25.

Cave

Kurz

Arlett

. Real-world data for regulatory decision making: challenges and possible solutions for Europe [published online ahead of print April 10, 2019]. Clin Pharmacol Ther. doi:10.1002/cpt.1426.

26.

US Food and Drug Administration. FDA Briefing Document. Oncologic Drugs Advisory Committee Meeting. https://www.fda.gov/media/121667/download) Updated February 26, 2019. Accessed March 20, 2019.